DISEASE BURDEN OF METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) IN CHINA

被引：0
|
作者：
Yu, M. [1 ]
Duan, X. [1 ]
Wang, J. [2 ]
Zhang, X. J. [2 ]
Yu, F. [2 ]
机构：
[1] Beijing North Med & Hlth Econ Res Ctr, Beijing, Peoples R China
[2] Xian Janssen Pharmaceut Ltd, Beijing, Peoples R China
来源：
VALUE IN HEALTH | 2021年 / 24卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN109
引用
收藏
页码：S39 / S40
页数：2
相关论文
共 50 条
  • [1] Disease burden and outcome in metastatic hormone sensitive prostate cancer (mHSPC).
    Albiges, Laurence
    Xie, Wanling
    Chen, Yu-Hui
    Boher, Jean-Marie
    Valenca, Loana Bueno
    Bernard, Brandon David
    Culine, Stephane
    Habibian, Muriel
    Carducci, Michael Anthony
    DiPaola, Robert S.
    Liu, Glenn
    Pomerantz, Mark
    Nakabayashi, Mari
    Kantoff, Philip W.
    Fizazi, Karim
    Gravis, Gwenaelle
    Sweeney, Christopher
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] TITAN study: evaluation of apalutamide in patients with metastatic hormone-sensitive prostate cancer - Treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
    Merseburger, Axel S.
    Suttmann, Henrik
    [J]. AKTUELLE UROLOGIE, 2021, 52 (02) : 155 - 160
  • [3] Use of abiraterone for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
    Cathomas, R.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 130 - 130
  • [4] Recent developments in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
    Schwentner, Christian
    [J]. AKTUELLE UROLOGIE, 2022, 53 (01) : 31 - 36
  • [5] Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm
    Weiner, Adam B.
    Nettey, Oluwarotimi S.
    Morgans, Alicia K.
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (09)
  • [6] IDENTIFYING AND CHARACTERIZING METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) POPULATION IN FINLAND
    Ruotsalainen, J.
    Korhonen, M. J.
    Purmonen, T.
    Joutseno, J.
    Saavuori, N.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S535 - S535
  • [7] Prognostic value of germline mutations in metastatic hormone-sensitive prostate cancer (mHSPC)
    Custodio-Cabello, Sara
    Pacheco-Barcia, Vilma
    Palka-Kotlowska, Magda
    Fernandez-Hernandez, Laura
    Del Alamo, Julio Fernandez
    Oliveros-Acebes, Eduardo
    Cabezon-Gutierrez, Luis
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 (10) : 331e13 - 331e24
  • [8] Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm
    Adam B. Weiner
    Oluwarotimi S. Nettey
    Alicia K. Morgans
    [J]. Current Treatment Options in Oncology, 2019, 20
  • [9] AUO First-line Therapy for metastatic hormone-sensitive Prostate Cancer (mHSPC)
    Rexer, H.
    Feyerabend, S.
    Graefen, M.
    [J]. UROLOGIE, 2023, 62 (04): : 441 - 442
  • [10] Efficacy of bi-weekly docetaxel in hormone-sensitive metastatic prostate cancer (mHSPC).
    Lombana Quinonez, Milton Alberto
    Milena Torres, Ana
    Gonzalez, Guido
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345